Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 725.28

+3.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/21/2018 11:10:28 AM
	Read Replies (1) of 3559

And, there is new problem, surfacing now is bit odd: finance.yahoo.com <Regeneron's Eye Drug Has Mysterious Rise in Side Effect Reports> <Last year, the side effect was reported in about 1 in 10,000 people who got Eylea, Mirza said. That’s less than what the company found in clinical trials, though in the real world doctors may not report every case. In about 70 percent of cases, including the current cluster, the reports came from more than one batch of the medicine -- suggesting the side effects aren’t being caused by a manufacturing error.> Well, IF it is a real clustering problem (manufacturing issue), as they described, FDA would order deep investigation and REGN would report problems on its own (at least I think that would be proper procedure). It may be due to distributing/doctor error how are vials handled. Refrigeration?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next